Re: Drug company interference in doctor/patient relationships?
From: Robert (Robert_at_hotmail.com)
Date: 08/10/04
- Next message: Frederick Von Mohrenberg: "Dermatology..Bullseye on skin"
- Previous message: Happy Dog: "Re: Please Help with Diagnosis"
- In reply to: Robert: "Re: Drug company interference in doctor/patient relationships?"
- Messages sorted by: [ date ] [ thread ]
Date: Mon, 9 Aug 2004 21:58:49 -0700
"Robert" <Robert@hotmail.com> wrote in message
I almost forgot this. Those damn whore canadian doctors are at it again.
Don't they have no shame. The thing costs $4,500 American dollares for one
small vial. Zee maybe you can do people a favor and see the pharm ties with
those people UOC. Who do they think will pay for that? Another week waiting
in non emergency situations can pay for that I guess.
The epidemiology of severe sepsis syndrome and its treatment with
recombinant human activated protein C.
Doig CJ, Laupland KB, Zygun DA, Manns BJ.
Department of Critical Care Medicine, Faculty of Medicine, University of
Calgary, Calgary AB, T2N 2T9, Canada. cdoig@ucalgary.ca
Severe sepsis syndrome has important consequences to healthcare systems as
the incidence is increasing, there is significant attributed morbidity and
mortality and there is a substantial cost for in-hospital and post-discharge
care. Current treatment includes the use of antimicrobials, local source
control and aggressive physiological support, usually in an intensive care
unit setting. Drotrecogin-alpha (activated) or recombinant human activated
protein C (rhAPC) is the only biological agent approved for use in severe
sepsis syndrome that has demonstrated efficacy in reducing 28-day all-cause
mortality and new data suggests a trend towards longer term survival.
However, given the evidence of a variable effect on survival rates in
patient subgroups and its acquisition cost, controversy has arisen
concerning its appropriate use. This review discusses the epidemiology of
sepsis, preclinical and clinical evidence supporting the use of rhAPC use,
controversies about the evidence of efficacy in severe sepsis syndrome and
cost-effectiveness data.
Publication Types:
Review
Review, Tutorial
PMID: 14521488 [PubMed - indexed for MEDLINE]
- Next message: Frederick Von Mohrenberg: "Dermatology..Bullseye on skin"
- Previous message: Happy Dog: "Re: Please Help with Diagnosis"
- In reply to: Robert: "Re: Drug company interference in doctor/patient relationships?"
- Messages sorted by: [ date ] [ thread ]
Relevant Pages
|